Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This study was undertaken to determine whether use of the direct renin inhibitor aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease, cardiovascular disease, or both. METHODS: In a double-blind fashion, we randomly assigned 8561 patients to aliskiren (300 mg daily) or placebo as an adjunct to an angiotensin-converting-enzyme inhibitor or an angiotensin-receptor blocker. The primary end point was a composite of the time to cardiovascular death or a first occurrence of cardiac arrest with resuscitation; nonfatal myocardial infarction; nonfatal stroke; unplanned hospitalization for heart failure; end-stage renal disease, death attributable to kidney failure, or the need for renal-replacement therapy with no dialysis or transplantation available or initiated; or doubling of the baseline serum creatinine level. RESULTS: The trial was stopped prematurely after the second interim efficacy analysis. After a median follow-up of 32.9 months, the primary end point had occurred in 783 patients (18.3%) assigned to aliskiren as compared with 732 (17.1%) assigned to placebo (hazard ratio, 1.08; 95% confidence interval [CI], 0.98 to 1.20; P=0.12). Effects on secondary renal end points were similar. Systolic and diastolic blood pressures were lower with aliskiren (between-group differences, 1.3 and 0.6 mm Hg, respectively) and the mean reduction in the urinary albumin-to-creatinine ratio was greater (between-group difference, 14 percentage points; 95% CI, 11 to 17). The proportion of patients with hyperkalemia (serum potassium level, ≥6 mmol per liter) was significantly higher in the aliskiren group than in the placebo group (11.2% vs. 7.2%), as was the proportion with reported hypotension (12.1% vs. 8.3%) (P<0.001 for both comparisons). CONCLUSIONS: The addition of aliskiren to standard therapy with renin-angiotensin system blockade in patients with type 2 diabetes who are at high risk for cardiovascular and renal events is not supported by these data and may even be harmful. (Funded by Novartis; ALTITUDE ClinicalTrials.gov number, NCT00549757.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ACE inhibitors and ARBs should not be used together and should be used with caution with spironolactone to avoid hyperkalemia or AKI.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [259]
In the citing paper
“However, combination therapy was associated with a higher rate of hyperkalemia and AKI, 85,86”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [86]
In the citing paper
“Long-term outcome trials in patients with diabetes and CKD demonstrated no kidney or cardiovascular bene fi t of RAS blockade with combined therapy to block the RAS versus the single use of RAS inhibitors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [86]
In the citing paper
“Prior trials of dual renin–angiotensin system blockade have failed to show cardiovascular or kidney protection among patients with CKD and type 2 diabetes”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [25]
In the citing paper
“markedly lower than in trials of dual RAS blockade (4.8% with combination therapy with a direct renin inhibitor and an ACE inhibitor or ARB 20 and 9.2% with dual ACE inhibitor and ARB therapy 22 )”
From Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes (2020) · cites this paper as [20]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationHaffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Levey, A. S., Coresh, J., Greene, T., Stevens, L. A., Zhang, Y. (., Hendriksen, S., Kusek, J. W., & Van Lente, F. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-4-200608150-00004 · Cited by 5,725
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Self-citationTelmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
Self-citation
Research works printed but not linked: 1
- Pfeffer MA, 2010, Dial Cardiovasc Med, 15, 130
Cited by
Items 501–600 of 1,000
Griffin, T. P., Wall, D., Browne, G. A., Dennedy, M. C., & O’Shea, P. M. (2017) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563217728964 · Cited by 21
Palmer, S. C., Ruospo, M., Teixeira-Pinto, A. M., Craig, J. C., Macaskill, P., & Strippoli, G. F. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.06.011 · Cited by 22
“Overall, 22 randomized trials involving 69,643 participants met the review eligibility criteria (Table 1).(19-40)”
BackgroundGheblawi, M., Wang, K., Viveiros, A., Nguyen, Q., Zhong, J., Turner, A. J., Raizada, M. K., Grant, M. B., & Oudit, G. Y. (2020) · Circulation Research · doi:10.1161/circresaha.120.317332 · Cited by 23
2023 Guideline for the management of hypertension in the elderly population in China
Hua, Q., Fan, L., Wang, Z., & Li, J. (2024) · 老年心脏病学杂志:英文版 · doi:10.26599/1671-5411.2024.06.001 · Cited by 23
Krum, H., McMurray, J. J. V., Abraham, W. T., Dickstein, K., Køber, L., Desai, A. S., Solomon, S. D., Chiang, Y., Gimpelewicz, C. R., Reimund, B., et al. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.408 · Cited by 21
Self-citationWish, J. B., & Pérgola, P. E. (2022) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2022.09.002 · Cited by 24
“3% of participants,(64) which was lower than that previously reported with dual RAS blockade with ACEi/ ARB.(41,45) Gynecomastia was found to be rare and comparable with placebo (0.”
BackgroundResultInfluentialAliskiren accumulation in the kidney
Lange, S., Fraune, C., Alenina, N. V., Bäder, M., Danser, A. H. J., Frenay, A.-R. S., van Goor, H., Stahl, R. A. K., Nguyen, G., Schwedhelm, E., et al. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e32835e226b · Cited by 20
“inhibitors to exploit the mechanisms for this accumulation and to see whether the renophilic properties of aliskiren could at least in part be responsible for the harmful effects seen in ALTITUDE [6].”
BackgroundInfluentialHeerspink, H. J. L., Oberbauer, R. W., Perco, P., Heinzel, A., Heinze, G., Mayer, G. J., & Mayer, B. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv210 · Cited by 20
“The ALiskiren TrIal in Type 2 diabetes Using carDiorenal End points (ALTITUDE) andVeterans Affair Nephropathy inDiabetes trials (VA NEPHRON-D) were stopped early because of more cases of worsening of renal function and hyperkalemia in the dual RAAS blockade treatment arm [16, 17].”
BackgroundAntihypertensive treatment and renal protection: Is there a J‐curve relationship?
Viazzi, F. C., Leoncini, G., Grassi, G. M., & Pontremoli, R. (2018) · Journal of Clinical Hypertension · doi:10.1111/jch.13396 · Cited by 20
Nassif, M. E., & Kosiborod, M. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.10.025 · Cited by 21
Kwakernaak, A. J., Waanders, F., Slagman, M. C. J., Dokter, M. M., Laverman, G. D., de Boer, R. A., & Navis, G. J. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e328364f5de · Cited by 21
“Dual blockade may have detrimental effects (for instance as observed in the ONTARGET trial [48] and the recently published ALTITUDE trial [49]).”
BackgroundSGLT2 inhibitors in non-diabetic kidney disease
Tesař, V. (2022) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/145734 · Cited by 21
Gilbert, C. J., Gomes, T., Mamdani, M., Hellings, C., Yao, Z., Garg, A. X., Wald, R., Harel, Z., & Juurlink, D. N. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.02.015 · Cited by 22
Long‐term case study of a Wuzhishan miniature pig with diabetes
Niu, M., Liu, Y., Xiang, L., Zhao, Y., Yuan, J., Jia, Y., Dai, X., & Chen, H. (2020) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12098 · Cited by 20
Donate‐Correa, J., Sánchez-Niño, M. D., González-Luis, A., Ferri, C. M., Martín-Olivera, A., Martín‐Núñez, E., Fernández‐Fernández, B., Tagua, V. G., Fernández, C. M., Ortíz, A., et al. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac143 · Cited by 20
Use of ACEi/ARBs, SGLT2 inhibitors and MRAs can help us reach the therapeutic ceiling in CKD
Sarafidis, P. A. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae014 · Cited by 24
Optimal blockade of the renin–angiotensin–aldosterone system
Nussberger, J., & Bohlender, J. M. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.28 · Cited by 21
Wong, M. Y. W., Saad, S., Zhang, J., Gross, S., Jarolimek, W., Schilter, H. C., Chen, J., Gill, A. J., Pollock, C. A., & Wong, M. G. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00698.2013 · Cited by 20
de Zeeuw, D., & Heerspink, H. J. L. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa013 · Cited by 20
Pan, X., Xu, S., Li, J., & Tong, N. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.599355 · Cited by 21
“At present, HF is one of the most common CVDs in patients with diabetes (7).”
BackgroundTherapeutic Vaccines against Human and Rat Renin in Spontaneously Hypertensive Rats
Qiu, Z., Chen, X., Zhou, Y., Lin, J., Ding, D., Yang, S., Chen, F., Wang, M., Zhu, F., Yu, X., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066420 · Cited by 19
“However, the ALTITUDE study in the aliskiren 300 mg arm was terminated in December 2011 because of futility and an increased incidence of serious adverse events such as hyperkalemia and renal impairment [33].”
BackgroundThe Amiloride-Sensitive Endothelial Sodium Channel and Vascular Tone
Warnock, D. G. (2013) · Hypertension · doi:10.1161/hypertensionaha.113.00768 · Cited by 19
Uzu, T., Araki, S.-I., Kashiwagi, A., Haneda, M., Koya, D., Yokoyama, H., Kida, Y., Ikebuchi, M., Nakamura, T., Nishimura, M., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0164936 · Cited by 18
The Enhanced Renin-Angiotensin-Aldosteron System Pharmacological Blockade - Which is the Best?
Tylicki, L., Lizakowski, S., Rutkowski, P., Renke, M., Sulikowska, B., Heleniak, Z., Donderski, R. Ł., Bednarski, R., Przybylska, M., Manitius, J., et al. (2012) · Kidney & Blood Pressure Research · doi:10.1159/000343391 · Cited by 18
Huang, R., Feng, Y., Wang, Y., Qin, X., Melgiri, N. D., Sun, Y., & Li, X. (2017) · PLoS ONE · doi:10.1371/journal.pone.0168582 · Cited by 18
Sedláková, L., Chábová, V. Č., Doleželová, Š., Škaroupková, P., Kopkan, L., Husková, Z., Červenková, L., Kikerlová, S., Vaněčková, I., Sadowski, J., et al. (2017) · Clinical and Experimental Hypertension · doi:10.1080/10641963.2016.1235184 · Cited by 19
Brunström, M., & Carlberg, B. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-026686 · Cited by 19
“Three trials were judged to be at high risk of bias for individual domains.(20) 24 26 We performed sensitivity analyses, testing the impact of these trials on our primary outcomes (online supplementary eFigure 16).”
BackgroundSugawara, H., Moniwa, N., Kuno, A., Ohwada, W., Osanami, A., Shibata, S., Kimura, Y., Abe, K., Gocho, Y., Tanno, M., et al. (2020) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2020.12.001 · Cited by 19
Ruiz‐Hurtado, G., & Ruilope, L. M. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvu023 · Cited by 19
Lin, C., Wu, Y.-T., Yang, W.-C., Tsai, M.-J., Liu, J., Yang, C., Li, S., Ou, S., Tarng, D., & Hsu, C.-C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189126 · Cited by 18
“A former Clinical trial on Aliskiren in Type 2 Diabetes and Cardiorenal End Points (ALTITUDE) choosing the direct renin inhibitor Aliskiren, instead of ACEI, as the second RAS blockade added on ARB in diabetic patients was terminated early because of increasing adverse events including stroke, hyperkalemia and renal c…”
ResultChallenges to Data Monitoring Committees When Regulatory Authorities Intervene
Swedberg, K. B., BORER, J. S., Pitt, B., Pocock, S., & Rouleau, J. L. (2016) · New England Journal of Medicine · doi:10.1056/nejmsb1601674 · Cited by 18
Adamczak, M., Kurnatowska, I., Naumnik, B., Stompór, T. P., Tylicki, L., & Krajewska, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312941 · Cited by 21
Recent advances in heart failure
Kassi, M., Hannawi, B., & Trachtenberg, B. H. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000497 · Cited by 17
Rydén, L., estable, G. D. T. D. L. S. E. D. C. S. D. Y. T. D. L. C. I., Grant, P. J., Anker, S. D., Berne, C., Cosentino, F., Danchin, N., Deaton, C., Escaned, J., Hammes, H. P., et al. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2013.10.015 · Cited by 37
Novel effective drugs for diabetic kidney disease? or not?
Gentile, G., Mastroluca, D., Ruggenenti, P. L., & Remuzzi, G. (2014) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.979151 · Cited by 18
“Unfortunately, the subsequent Aliskiren Trial In Type 2 Diabetes Using Cardio-Renal Disease Endpoints (ALTITUDE) trial was ceased prematurely due to predicted futility for the primary composite outcome of CV death or heart failure hospitalization and adverse outcomes, including hypotension, hyperkalemia, renal impairm…”
BackgroundPractical Applications for Single Pill Combinations in the Cardiovascular Continuum
Iellamo, F., Werdan, K., Narkiewicz, K., Rosano, G. M. C., Volterrani, M., Dipartimento di Scienze Mediche, I. D. R. E. C. A. C. S. S. R. P., Dipartimento di Scienze Mediche, I. D. R. E. C. A. C. S. S. R. P., & Dipartimento di Scienze Mediche, I. D. R. E. C. A. C. S. S. R. P. (2017) · Cardiac failure review · doi:10.15420/cfr.2017:5:1 · Cited by 19
“In the 2008 Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET), the combination of an ACE inhibitor with an ARB resulted in cases of severe renal failure,(29) and in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) study, in which a direct renin in…”
BackgroundModulation of the Renin-Angiotensin-Aldosterone System in Heart Failure
Casella, G., Struthers, A. D., & Lang, C. C. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0403-7 · Cited by 20
Achieving remission of proteinuria in childhood CKD
Ruggenenti, P. L., Cravedi, P., Chianca, A., Caruso, R., & Remuzzi, G. (2016) · Pediatric Nephrology · doi:10.1007/s00467-016-3495-1 · Cited by 18
“Two other studies, the VA NEPHRON D [37] and the ALTITUDE [38] trials, found that dual RAAS blockade with an ACE inhibitor [37] or a renin inhibitor [38] as add-on therapy to ARBs failed to improve nephroprotection as compared to ARB monotherapy in type 2 diabetes patients with nephropathy and was associated with more…”
Burggraaf, B., & Cabezas, M. C. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.04.017 · Cited by 18
The Function of Renin and the Role of Food-Derived Peptides as Direct Renin Inhibitors
Pihlanto, A., & Mäkinen, S. (2017) · InTech eBooks · doi:10.5772/intechopen.69513 · Cited by 17
“It has been found to be a more effective antihypertensive agent than ACE inhibitors [74], but recent clinical evidence suggests that Aliskiren may be harmful to patients with type 2 diabetes who are at risk of developing cardiovascular and renal diseases [54].”
BackgroundQiu, M., Li, S., Jin, L., Feng, P., Kong, Y., Zhao, X., Lin, Y., Xu, Y., Li, C., & Wang, W. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0818-1 · Cited by 18
“[42], as chymostatin acts intracellularly.”
Sridhar, V. S., Liu, H., & Cherney, D. Z. I. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.02.324 · Cited by 19
Arici, M., ALTUN, B., Araz, M., Atmaca, A. A., Demir, T., Ecder, T., Güz, G., Yavuz, D. G., Yildiz, A., & Yilmaz, T. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1384454 · Cited by 19
“…reported in trials of dual RAS blockade (4.8% with a direct renin inhibitor plus an ACEi or ARB and 9.2% with dual ACEi-ARB therapy), despite FIDELIO-DKD had no protocol recommendations to restrict dietary potassium or potassium supplements in contrast to studies of dual RAS blockade (20, 60, 61).”
BackgroundResultInfluentialInhibition of the renin–angiotensin system for lowering coronary artery disease risk
Sheppard, R. J., & Schiffrin, E. L. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.03.001 · Cited by 16
Recent advances in treatment of heart failure
Kitai, T., & Tang, W. H. W. (2015) · F1000Research · doi:10.12688/f1000research.7022.1 · Cited by 18
Pharmacologic management of angioedema induced by angiotensin-converting enzyme inhibitors
Scalese, M. J., & Reinaker, T. S. (2016) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp150482 · Cited by 18
Established and Emerging Strategies in the Treatment of Chronic Kidney Disease
Pena-Polanco, J. E., & Fried, L. F. (2016) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2016.05.009 · Cited by 16
Pharmacological interventions for heart failure in people with chronic kidney disease
Ravani, P., Quinn, R. R., & Strippoli, G. F. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012466 · Cited by 16
Wang, M., Wang, Z., Zhou, J., Sun, W., Wang, Y., Han, M., Yang, H., Liu, W. J., & Wang, Y. (2018) · Trials · doi:10.1186/s13063-018-2749-6 · Cited by 21
Representing the KNOW-CKD Investigators Group, Kim, H., Park, S., Jhee, J. H., Yun, H.-R., Park, J. T., Han, S. H., Lee, J., Kim, S. W., Kim, Y. H., et al. (2019) · BMC Nephrology · doi:10.1186/s12882-019-1292-3 · Cited by 16
McCoy, I. E., Han, J., Montez‐Rath, M. E., Chertow, G. M., & Rhee, J. J. (2020) · Clinical Diabetes · doi:10.2337/cd19-0087 · Cited by 17
the directors of the JCS, J., Araki, E., Tanaka, A., Inagaki, N., Ito, H., Ueki, K., Murohara, T., Imai, K., Sata, M., Sugiyama, T., et al. (2020) · Diabetology International · doi:10.1007/s13340-020-00471-5 · Cited by 17
“If present, an angiotensin-converting enzyme (ACE) inhibitor (which is a renin–angiotensin system (RAS) inhibitor) or angiotensin-receptor blocker (ARB) is first considered.”
BackgroundInfluentialShenoy, S. V., Nagaraju, S. P., Bhojaraja, M. V., Prabhu, R., Rangaswamy, D., & Rao, I. R. (2021) · Nephrology · doi:10.1111/nep.13917 · Cited by 18
Hypertension mediated kidney and cardiovascular damage and risk stratification: Redefining concepts
Márquez, D. F., Rodríguez‐Sánchez, E., Segura, J., Ruilope, L. M., & Ruiz‐Hurtado, G. (2022) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2021.10.008 · Cited by 21
New data do not SUPPORT triple RAAS blockade
Danser, A. H. J., & van den Meiracker, A. H. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.30 · Cited by 16
Satirapoj, B., Kaewput, W., Supasyndh, O., & Ruangkanchanasetr, P. (2015) · Journal of Diabetes Research · doi:10.1155/2015/172038 · Cited by 16
Individualization of Antihypertensive Drug Treatment
Mancia, G., & Grassi, G. M. (2013) · Diabetes Care · doi:10.2337/dcs13-2013 · Cited by 17
“Indeed, in diabetic patients administration of this drug on the background of an ACE inhibitor or an angiotensin receptor antagonist has recently been shown to have unfavorable therapeutic effects (56).”
BackgroundRefining Long-Term Prediction of Cardiovascular Risk in Diabetes – The VILDIA Score
Goliasch, G., Silbernagel, G., Kleber, M. E., Grammer, T. B., Pilz, S., Tomaschitz, A., Bartko, P. E., Maurer, G., Köenig, W., Niessner, A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-04935-8 · Cited by 18
“Moderate 38% (82) 55% (97) 17% (38) 100% (217)”
FHL2 mediates podocyte Rac1 activation and foot process effacement in hypertensive nephropathy
Li, S., Chu, P., Huang, P., Hsieh, T., Suszták, K., & Tarng, D. (2019) · Scientific Reports · doi:10.1038/s41598-019-42328-1 · Cited by 16
Complications of Diabetes Mellitus
Brownlee, M., Aiello, L. P., Cooper, M. E., Vinik, A. I., Nesto, R. W., & Boulton, A. J. M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00033-x · Cited by 22
Serum Potassium and Cardiovascular Outcomes: The Highs and the Lows
Toto, R. D. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00030117 · Cited by 16
Ahmed, R., de Souza, R. J., Li, V., Banfield, L. E., & Anand, S. S. (2024) · Diabetologia · doi:10.1007/s00125-023-06052-w · Cited by 16
“Seven trials [29, 53, 57, 60, 78, 79, 89], however, had a PPR >1, with racialised PPRs of 1.85, 1.47, 1.18, 1.04, 1.15, 1.06, 1.67, respectively.”
BackgroundInfluentialOral hypoglycemic agents and the heart failure conundrum: Lessons from and for outcome trials
Kappel, B. A., Marx, N., & Federici, M. (2015) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2015.06.006 · Cited by 17
“Moreover, it is worth noting that in most diabetes trials such as Look AHEAD [8], RENAAL [9], PROactive [10] and ALTITUDE trial [11], the incidence of HF is evenmore common than that of other CV events such as stroke and myocardial infarction (MI).”
BackgroundIchikawa, D., Kamijo‐Ikemori, A., Sugaya, T., Shibagaki, Y., Yasuda, T., Katayama, K., Hoshino, S., Igarashi-Migitaka, J., Hirata, K., & Kimura, K. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00460.2013 · Cited by 15
Does cardiovascular protection translate into renal protection?
Ruiz‐Hurtado, G., & Ruilope, L. M. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.97 · Cited by 16
Chen, K., Zhang, J., Guan, T., & Zhang, S. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s75111 · Cited by 17
“The primary outcomes were major cardiovascular events available in five trials, total mortality in six trials, cardiac death in four trials,(9,11,22,24) myocardial infarction in four trials, 9,11,22,24 and stroke in three trials.(9,11,24) Although the included trials rarely reported on the key indicators of trial qual…”
Update on role of direct renin inhibitor in diabetic kidney disease
Dhakarwal, P., Agrawal, V., Kumar, A., Goli, K. M., & Agrawal, V. (2014) · Renal Failure · doi:10.3109/0886022x.2014.900425 · Cited by 16
“The ALTITUDE trial, as discussed earlier, failed to show additional significant benefit of dual therapy on combined cardiovascular and renal outcomes and the trial had to be stopped early as recommended by the data monitoring committee.(56) Significantly more ‘‘renal adverse effects’’ especially hypotension, hyperkale…”
ResultHalimi, J., Joly, D. A., Combe, C., Choukroun, G. J., Dussol, B., Fauvel, J., Quéré, S., & Fiquet, B. (2016) · BMC Nephrology · doi:10.1186/s12882-016-0336-1 · Cited by 19
“At baseline, 23 % of our patients were on a dual RAS blockade, and in spite of changes in recommendations following ALTITUDE publication [34], a full 20 % were taking two RAS blockers after the 2-year follow-up, although aliskirenbased dual blockades had considerably decreased.”
BackgroundResultInfluentialSGLT-2 Inhibition: A Potential New Treatment for Diabetic Kidney Disease?
Toto, R. D. (2017) · The Nephron journals/Nephron journals · doi:10.1159/000450895 · Cited by 15
Zheng, S. L., Roddick, A., & Ayis, S. A. (2017) · Diabetes and Vascular Disease Research · doi:10.1177/1479164117715854 · Cited by 15
Hyperkalemia in the Hypertensive Patient
Lakkis, J. I., & Weir, M. R. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-0954-2 · Cited by 16
The use of aliskiren as an antifibrotic drug in experimental models: A systematic review
Marin, T. A., Bertassoli, B. M., Carvalho, A. A. D. S., & Feder, D. (2019) · Drug Development Research · doi:10.1002/ddr.21610 · Cited by 15
Zhao, Q., Shen, J., Lu, J., Jiang, Q., & Wang, Y. (2020) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01442-z · Cited by 16
Yaribeygi, H., Maleki, M., Sathyapalan, T., Jamialahmadi, T., & Sahebkar, A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117916 · Cited by 15
Simin, Z., Li, J., & Zhao, X. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13940 · Cited by 17
Sánchez, M. A. (2013) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2013.08.003 · Cited by 17
Liu, C., Periasamy, S., Chang, C., Mo, F., & Liu, M. (2013) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607113491781 · Cited by 15
Update on Blood Pressure Control and Renal Outcomes in Diabetes Mellitus
Joven, M. H., & Anderson, R. J. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0613-6 · Cited by 18
Effect of aliskiren on vascular remodelling in small retinal circulation
Jumar, A., Ott, C., Kistner, I., Friedrich, S., Schmidt, S., Harazny, J. M., & Schmieder, R. E. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000735 · Cited by 15
“Differences in the study populations are the major difference between our study and the ALTITUDE trial [44], where patients with diabetes mellitus type 2 and chronic kidney disease, cardiovascular disease or both [22] were recruited.”
ResultRenal end points in clinical trials of kidney disease
Weldegiorgis, M. T., de Zeeuw, D., & Heerspink, H. J. L. (2015) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000118 · Cited by 16
“landmark clinical trials in renal and cardiovascular disease [3,4], it is subject to debate for several reasons.”
BackgroundÖsterreichischer Blutdruckkonsens 2019
Hypertensiologie, Ö. G. F., Weber, T., Atherosklerosegesellschaft, Ö., Gesellschaft, Ö. D., Angiologie, Ö. G. F. I., Nephrologie, Ö. G. F., Gesellschaft, Ö. K., Neurologie, Ö. G. F., Schlaganfall-Gesellschaft, Ö., Allgemeinmedizin, Ö. G. F., et al. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-019-01565-0 · Cited by 18
Idzerda, N. M. A., Clegg, L. E., Hernandez, A. F., Bakris, G. L., Penland, R. C., Boulton, D. W., Bethel, M. A., Holman, R. R., & Heerspink, H. J. L. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13958 · Cited by 16
“For this analysis, the relationships between risk markers and renal outcomes were established at baseline in a background population derived from the ALTITUDE trial, a study in patients with T2D at high cardiovascular and renal risk.(13) A subgroup of patients with urine albumin:creatinine ratio (UACR) <400 mg/g and e…”
MethodHipertensão arterial sistêmica primária
Nobre, F. D., Coelho, E. B., Lopes, P. C., & Geleilete, T. J. M. (2013) · Medicina (Ribeirão Preto) · doi:10.11606/issn.2176-7262.v46i3p256-272 · Cited by 83
Drug therapies to delay the progression of chronic kidney disease
Ward, F. L., Holian, J., & Murray, P. T. (2015) · Clinical Medicine · doi:10.7861/clinmedicine.15-6-550 · Cited by 18
Kim, H., Park, J., Nam, K. H., Jhee, J. H., Yun, H., Park, J. T., Han, S. H., Chung, W., Oh, K., Park, S. K., et al. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy403 · Cited by 18
CKDs at the Crossroads: From Failures to Future Therapies
Wehbe, F., Elliott, M., & Levin, A. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.09.050 · Cited by 17
Residual Renal Risk in Diabetic Nephropathy Despite Contemporary Therapies
Speeckaert, R., Delrue, C., & Speeckaert, M. M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15030921 · Cited by 17
Min, K.-D., Matsumoto, Y., Asakura, M., & Ishihara, M. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14811 · Cited by 16
The Population Risks of Dietary Salt Excess Are Exaggerated
Mente, A., O'Donnell, M. J., & Yusuf, S. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.02.003 · Cited by 15
Liu, F., Sun, Q., WANG, L., Nie, S., & Li, J. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3452 · Cited by 14
Weinrauch, L. A., D’Elia, J. A., Finn, P. V., Lewis, E. F., Desai, A. S., Claggett, B. L., Cooper, M. E., & McGill, J. B. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.12.021 · Cited by 14
“However, combinations of angiotensin converting enzyme inhibitors and angiotensin receptor blockers or direct renin inhibitors do not improve outcomes [5–7].”
BackgroundSelf-citationSourij, H., Aberer, F., Antlanger, M., Brix, J., Cejka, D., Clodi, M., Edlinger, R., Eller, K., Horn, S., Kaser, S., et al. (2016) · Wiener klinische Wochenschrift · doi:10.1007/s00508-016-0992-y · Cited by 14
Ziff, O. J., Covic, A. C., & Goldsmith, D. J. A. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12803 · Cited by 14
Blood pressure targets for hypertension in patients with type 2 diabetes
Aronow, W. S., & Shamliyan, T. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.04.36 · Cited by 18
Selective endothelin A receptor antagonism in patients with proteinuric chronic kidney disease
Provenzano, M., Andreucci, M., Garofalo, C., Minutolo, R., Serra, R., & Nicola, L. D. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1869720 · Cited by 14
Renal events in patients receiving neprilysin inhibitors: a systematic review and meta-analysis
Barbosa, C. V., Lang, H., Melk, A., & Schmidt, B. M. W. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac001 · Cited by 18
Cruz‐López, E. O., Ren, L., Uijl, E., Groningen, M. C. C., van Veghel, R., Garrelds, I. M., Domenig, O., Poglitsch, M., Zlatev, I., Rooney, T., et al. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15955 · Cited by 15
The Polypill: A New Alternative in the Prevention and Treatment of Cardiovascular Disease
Espinosa, E. V. P., Mato, E., Guzmán, D. M. S., & Khasawneh, F. T. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113179 · Cited by 14
Schievink, B., Heerspink, H. J. L., Leufkens, H. G. M., de Zeeuw, D., & Hoekman, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108722 · Cited by 16
“For example, the anti-diabetic medicine rosiglitazone reduces the surrogate HbA1c, yet increases the risk of myocardial infarction [12,13]; the antihypertensive medicine aliskiren increased the risk of stroke in the ALTITUDE trial despite reducing blood pressure and albuminuria [14,15], and sibutramine increases risk…”
BackgroundAssessment and management of resistant hypertension
Padwal, R. S., Rabkin, S. W., & Khan, N. A. (2014) · Canadian Medical Association Journal · doi:10.1503/cmaj.130764 · Cited by 16
Metadata
- Authors
- Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., Richard, A., Xiang, Z., Brunel, P., & Pfeffer, M. A.
- Affiliations
- University of Copenhagen (DK)
- Brigham and Women's Hospital (US)
- The University of Texas at San Antonio Health Science Center (US)
- Imperial College London (GB)
- Steno Diabetes Centers (DK)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-12-06
- Volume
- 367
- Issue
- 23
- Pages
- 2204-2213
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138862624
- Cited by
- 1,319
- References
- 40
- Citations by year
- 2026: 30 · 2025: 41 · 2024: 52 · 2023: 68 · 2022: 61 · 2021: 75 · 2020: 73 · 2019: 96 · 2018: 93 · 2017: 124 · 2016: 117 · 2015: 151 · 2014: 166 · 2013: 159 · 2012: 11
- FWCI
- 100.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Research Bank (Australian Catholic University) (submittedVersion)
- Institutional Research Information System (University of Udine) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- IRIS (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- UnissResearch (Università degli Studi di Sassari) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Open Access CRIS of the University of Bern
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- aliskiren, type 2 diabetes, chronic kidney disease, renin-angiotensin system blockade, ACE inhibitors, angiotensin receptor blockers, cardiovascular events, end-stage renal disease, hyperkalemia, hypotension, albumin-creatinine ratio, blood pressure reduction, cardiorenal outcomes
- MeSH terms
- Renin Inhibitors, Aged, Amides, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Fumarates, Humans, Hyperkalemia, Hypokalemia, Kidney Diseases, Male, Middle Aged, Patient Dropouts, Treatment Failure, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.